• Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Menu
  • Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Search
Close
All ASPIRIN SUMMARIES

ISSUE 2020 (11)

ASPIRIN SUMMARIES: Low-dose aspirin for the prevention of coronary and cerebrovascular events

Table of Contents

Download PDF

Low-dose aspirin for the prevention of coronary and cerebrovascular events

This Aspirin Summary focuses on the research behind the development of effective, well tolerated, low-dose aspirin antithrombotic therapy for reducing the incidence of heart attack and stroke. This year’s 2020 International Aspirin Foundation’s Senior Science Award has been given to the scientists behind four of the first trials to increase our understanding of low-dose aspirin’s role in cardiovascular disease (CVD) prevention.  The following summaries explore this work.

 

The long-term effects of low-dose aspirin after unstable coronary artery disease (The Research Group on Instability in Coronary Artery Disease [RISC] in Southeast Sweden).

Coronary artery disease (CAD) progresses due to atherosclerosis in which deposits of cholesterol clog the coronary arteries and when a plaque or cholesterol deposit bursts and causes a blood clot to block the supply of blood to the heart. Unstable CAD, [defined as unstable angina or non-Q wavemyocardial infarction (MI)] results from these processes. The RISC study group hypothesised that the risk of further CAD events could be reduced by using antiplatelet therapy and that this might not only decrease the risk of an MI by helping to prevent a clot but would also improve coronary blood flow and thereby diminish the symptoms of angina and the need for coronary angiography and revascularisation.

Although previous studies had demonstrated the protective effect of higher doses of aspirin [165- 1500mg] after MI and unstable angina and the RISC study group had shown 75mg/day of aspirin to be effective at reducing CAD events in the first 3months after an episode of CAD instability, this was the first study to look at the protective effect of 75mg/ day of aspirin on CAD events [MI, angina, coronary angiogram and revascularisation] over a period of long- term follow up.

This study was designed as a prospective, randomised, double-blind, placebo-controlled trial which included 796men [less than 70 years old] with unstable CAD in order to evaluate the impact of 75mg/day of aspirin over at least a year on further CAD events.

After one year the researchers found that when compared with placebo, low-dose aspirin treatment reduced the risk of having an MI or dying [risk ratio 0.52 (confidence interval 0.37 to 0.72)]. Severe angina needing a referral to coronary angiography was also reduced [risk ratio 0.71 (confidence interval 0.56 to 0.91)].

The authors state:

“The reduction of combined events- death, myocardial infarction and refractory angina – during 1 year of treatment with aspirin (75mg/day) was impressive and side effects were rare. Aspirin at this dose is extremely inexpensive and the treatment will be very cost-effective.”“

For further information please see:

Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol. 1991, Dec,18; (7):1587-93. DOI:10.1016/0735-1097(91)90489-v

 

The Dutch TIA trial study group compare a 30 mg daily dose of aspirin daily with a 283 mg daily dose for people who have had a TIA or minor ischemic stroke and find it as effective at improving vascular outcomes with less adverse events

In this randomised, double-blind, controlled clinical trial a 30mg versus a 283mg daily dose of aspirin was compared for effectiveness in reducing death from all vascular causes, stroke ormyocardial infarction (MI) in 3131 people who had experienced a transient ischemic attack (TIA) or minor stroke.  The mean follow-up of study participants was 2.6 years.

In the group taking the 30mg aspirin dose the frequency of vascular events [death from vascular causes, nonfatal stroke, or non fatal myocardial] was 14.7% [228 out of 1555] versus 15.2% [240 out of 1576] in those on the higher 283mg daily dose. The low-dose aspirin group demonstrated amore favourable safety profile with slightly fewer major bleeding events [40 versus 53], significantly fewer minor bleeding events [49 versus 84] and fewer gastrointestinal side effects [164 versus 179].The incidence of major bleeding events was found to be low in both study doses with a 2.6 % incidence in the 30mg group and 3.2% in those taking 283mg.

It is important to note that when very low-dose aspirin is used it can take a few days to achieve maximal inhibition of platelets. Because of this a loading dose of 120mg of aspirin is recommended by the authors. The formulation of aspirin used to provide the 30mg dose in this trial was with 38mg of carbaspirin calcium (Ascal) which contains 30mg of aspirin and unlike plain aspirin this formulation is freely water soluble which may be critically important for the absorption of very low-dose aspirin.

The authors conclude:

“Our data indicate that 30 mg of aspirin daily is no less effective in the prevention of vascular events than a 283-mg dose in patients with a transient ischemic attack or minor stroke, and has fewer adverse effects.”

For further information please see:

VanGijn J and The Dutch TIA Trial StudyGroup. A comparison of two doses of aspirin (30mg vs. 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl JMed. 1991,Oct, 31; 325:1261-1266. DOI:10.1056/NEJM199110313251

 

The Swedish Aspirin Low-dose Trial (SALT) – 75mg of aspirin daily found to be effective for secondary prevention after TIA or minor stroke

The aim of the SALT study was to investigate the efficacy of 75mg of aspirin daily for the prevention of stroke and death after people had experienced a minor stroke or transient ischaemic attack (TIA). At this point in time doses of 300mg and above of aspirin were well established for this indication but the researchers were aware lower doses also inhibit platelet function with a probable lower risk of side effects. Experiments had shown that doses as low as 1-2mg/kg body weight was enough to inhibit platelet function in vitro.

This randomised, placebo-controlled study followed 1360 patients for a median of 32months and found that 75mg of aspirin daily resulted in an 18% reduction in stroke or death (relative risk 0.82, 95% confidence interval 0.67-0.99; log-rank analysis p=0.02) when compared with placebo. Secondary outcomes of stroke or two or more TIAs within a week of each other requiring a change in therapy or myocardial infarction showed a16-20% reduction when compared with placebo.  There were 147 adverse events reported in those taking aspirin (22%) and 123 in the placebo group (18%). Interestingly gastrointestinal side effects (excluding bleeding) was only slightly more often seen in the aspirin group, however there was a significant excess in bleeding in those taking aspirin (p=0.04).

This was the first randomised controlled trial to show the beneficial effects of aspirin for secondary prevention after TIA or minor stroke at a dose of less than 300 mg daily.  The risk reduction was similar to that found in data from a meta-analysis of trials completed by 1988. The researchers found that side effects however were less than in any previous long-term secondary prevention trial.

The authors put their finding into the context of other studies, including ISIS-2 (aspirin daily dose 162mg), the RISC study (aspirin daily dose 75mg), the Dutch TIA trial (no difference between daily aspirin doses of 30 mg and 283mg) and the data from the metanalysis of trials before 1988 (Antiplatelet Trialists Collaboration) and conclude that there is very little difference in CVD risk reduction with low-dose aspirin.  They point out however that although a risk reduction of 17-25% is very useful it is not the sole answer to the problem and that risk factor reduction is also important as part of a combined strategy to prevent cardiovascular events.

The authors state:

“Thus, we have found that a low dose (75 mg/day) of aspirin significantly reduces the risk of stroke or death in patients with cerebrovascular ischaemic events.“

For further information please see:

Norving Bo and The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The Lancet.1991, Nov,30; 338 (8779): 1345-1349. DOI:10.1016/0140-6736(91)92233-R

 

Aspirin reduces non-fatal ischaemic heart disease in high risk men.

This trial had four factorial treatment groups: active warfarin and active aspirin (n = 1277); active warfarin and placebo aspirin (n=1268); placebo warfarin and active aspirin (n=1268); and placebo warfarin and placebo aspirin (n=1272). A dose of 75mg daily in a controlled release formulation, was used for aspirin. The intention was that this would maximise thromboxane inhibition but spare prostacyclin.  This low-dose aspirin use was found to reduce ischaemic heart disease (IHD) events by 20% (1-35, p=0.04)mainly due to a 32% reduction in non-fatal IHD (12-48, p=0.004). In this study low-dose aspirin use resulted in an absolute reduction in IHD of 2.3 per 1000 person years.  The study found that combined treatment with warfarin and low- dose aspirin was more effective than using either agent alone. Bleeding side effects were however higher with the warfarin and aspirin regimen showing an increase in haemorrhagic and fatal strokes. In addition, there were 15 ruptured aortic or dissecting aneurysms in those taking warfarin compared with only 3 in those not on warfarin (p=0.01).

The study was carried out in men aged 49-69 years across 108 group practices within the Medical Research Council’s (MRC)General Practice Research Framework across the UK.  Men in the top 20-25% of the risk score distribution were selected and screened for suitability.

This adds to the data for low-dose aspirin and because of its nationwide general practice setting the results are very representative of real life.

The authors state that:

“The results on combined treatment with both warfarin and aspirin on all IHD further support the likelihood that simultaneously modifying fibrin production and platelet function is more effective than either approach on its own.”

For further information please see:

Meade TW. And the Medical Research Council’s General Practice Research Framework.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Lancet. 1998, Jan,24; 351: 233-241.

It is also useful to read the correspondence section discussing this trial in The Lancet 1998; Apr, 18; 351: 1204-1207.

 

Commentary and 2020 update

Together these four trials not only show that low-dose aspirin is as effective and better tolerated than conventional doses; it also gives insight into how aspirin is working within this antithrombotic setting. Platelet thromboxane is completely suppressed by low- dose aspirin yet prostacyclin production by the vessel wall may still be partly preserved, important for the COX-1 protective role in the stomach lining.

The ground-breaking work of Lars Wallentin, Jan van Gijn, Bo Norrving and Tom Meade and their research teams established low-dose aspirin as an antithrombotic therapy within both cardiovascular and neurological clinical practice. In 2020 this work continues to inspire antithrombotic research and is still recognised in the latest guideline updates as demonstrated in a selection of 2020 publications to follow.

 

Aspirin immediately after TIA reduces the risk and severity of early recurrent stroke.

In this editorial, Professor Rothwell emphasises the risk of having a major stroke after a TIA or minor stroke, which can be as high as 10 % and explores the best ways to minimise this.

Rothwell explains that other single antiplatelet therapies have not been found to be better than aspirin during this acute post transient Ischaemic attack (TIA) or minor stroke high risk phase.  He discussed the recent trial work comparing ticagrelor and low-dose aspirin (dual antiplatelet therapy) with low-dose aspirin alone (see below for summary Johnston et al. 2020).Whilst the combination of ticagrelor and aspirin did reduce the incidence of recurrent stroke or death it was associated with a higher risk of serous bleeding and there was no overall significant benefit in terms of disability or death.

Rothwell points out that the dual antiplatelet trials with aspirin and clopidogrel or ticagrelor have recruited only high-risk patients and of these only the highest risk group benefitted from dual antiplatelet therapy. Thus, bleeding risk from using two antiplatelet drugs may exceed the benefit in reducing subsequent cardiovascular events in everyday practice.

Rothwell concludes with a call for action:

“Regardless of which combination of antiplatelet drugs is favoured for the high-risk minority, all patients should receive aspirin immediately after TIA unless aspirin is contraindicated. Too many patients are sent home from emergency departments without this simple treatment that substantially reduces the risk and severity of early recurrent stroke.”

For further information please see:

Rothwell PM. Antiplatelet treatment to prevent early recurrent stroke. N Engl JMed. 2020, Jul,16; 383:276-278. DOI: 10.1056/NEJMe2018927

 

Dual antiplatelets (aspirin plus ticagrelor) have no significant benefit on disability or death

In the THALES (Acute Stroke or Transient Ischaemic Attack treated with ticagrelor and ASA for Prevention of Stroke and Death) trial, 11,016 patients were randomised to receive either low-dose aspirin plus placebo or low-dose aspirin in combination with ticagrelor immediately following mild-to-moderate non cardioembolic ischemic stroke or high-risk TIA.  The aspirin was given in a loading dose of 300-325mg on the first day (within 24 hours of the event) and then at a dose of 75-100mg for 30 days.

Primary outcome events (a composite of stroke or death within 30 days) occurred in 303 patients (5.5%) in the combination antiplatelet group compared with 362 people (6.6%) in the low-dose aspirin plus placebo group (hazard ratio, 0.83;95% confidence interval [CI], 0.71 to 0.96; P=0.02).

The combination group had 276 patients with ischemic stroke (5%) compared with 345 (6.3%) in the single antiplatelet group (hazard ratio, 0.79;95% [CI], 0.68 to 0.93; P=0.004).However serious bleeding events were experienced in 28 patients (0.5%) taking combination antiplatelets when compared with 7 patients in the low- dose aspirin plus placebo group (0.1%) (P=0.001).The incidence of disability was not significantly different between the two groups.

The number needed to treat to prevent one primary outcome event with the combination antiplatelet therapy was 92 with the number needed to harm from a severe bleeding rate at 263.

For further information please see:

Johnston SC, Amarenco P, DenisonH et al. Ticagrelor and aspirin or aspirin alone in acute stroke or TIA. N Engl JMed. 2020, Jul,16; 383:207-217. DOI: 10.1056/NEJM0a1916870

 

A meta-analysis concludes that monotherapy with low-dose aspirin is comparable with P2Y12 inhibitor monotherapy for the secondary prevention of cardiovascular disease.

Chiarito and colleagues conducted a systematic review and meta-analysis of all randomised trials that compare P2Y12 inhibitors with low-dose aspirin monotherapy for the prevention of secondary cardiovascular (CV) events in patients with established cerebrovascular, coronary or peripheral artery disease with the aim of finding the optimal regimen.

The researchers found nine trials with a total of 42 108 patients that met their study criteria.  The resulting meta- analysis showed that the risk of having amyocardial infarction (MI) was marginally lower in those taking any P2Y12 inhibitor when compared with aspirin (OR 0.81[95% CI 0.66-0.99]; I2=10.9%). The clinical significance of this was questioned by the authors particularly as they estimated that the number needed to treat to prevent one MI was 244.There was no difference in the risk of having a stroke, all-cause death, vascular death or major bleeding between the low-dose aspirin or any of the P2Y12 monotherapy regimens. Low-dose aspirin is more cost effective and still the drug of choice in current guidelines looking at secondary CV prevention.

In the Lancet comments section, Professor Robert Byrne, Director of Cardiology at the Mater Private Hospital, Dublin and Chair of Cardiovascular Research at the Royal College of Surgeons, remarks that the study was well designed to compare low-dose aspirin with P2Y12 inhibitors and relevant for the discussion around optimal antithrombotic therapy in people who have established cardiovascular disease.

Professor Byrne points out that low-dose aspirin monotherapy remains the standard-of- care for the secondary prevention of CV events and despite trial work to either replace low-dose aspirin with other antiplatelets or improve regimens by either adding a P2Y12 inhibitor or a low-dose anticoagulant such as rivaroxaban the results have not changed recent updates to the European Society of Cardiology guidelines where low-dose aspirin remains the drug of choice for secondary prevention in people with chronic coronary syndrome

He states:

“our impression is that the absence of substantial difference between the two approaches supports the use of aspirin-the drug is easier to take, associated with less non-compliance, fewer off-target side effects (compared with ticagrelor in particular), and less variation in treatment response (compared with clopidogrel), and is likely to be more cost-effective.”

For further information please see:

Chiarito M, Sanz-Sánchez J, Cannata F, et al.  Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.  The Lancet. 2020,May,09; 395:1487-95. DOI: 10.1016/SO140-6736(20)30315-9.

Byrne R. Aspirin for secondary prevention of cardiovascular disease.  The Lancet. 2020,May,9; 395:1462-1463. DOI:10.1016/S0140-6736(20)30799-6.

Knuuti J,WijnsW, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. EurHeart J. 2020, Jan,14; 41: 407-77. DOI:10.1093/eurheartj/ehz425.

 

NICE guidelines recommend low-dose aspirin for the primary prevention of cardiovascular disease in those at high risk of myocardial infarction or stroke.

Whilst the NICE clinical knowledge summary advises against routinely prescribing antiplatelet therapy for the primary prevention of cardiovascular disease, they do suggest considering it for those with a high CVD risk score. In deciding whether or not to use aspirin in this group of people it is important to consider that low- dose aspirin does not have a license for primary CVD prevention, that there are other ways to reduce CVD risk (e.g. smoking cessation or taking a statin tablet) and that whilst the evidence for benefit is limited there is a risk of doing harm and that it is important to discuss these risks and benefits with the patient.

NICE CKS Antiplatelet treatment. [updated August 2020; cited 2020 Oct 6] Available from:  https://cks.nice.org.uk/topics/antiplatelet-treatment/

For further information about aspirin and current guidelines please see our UK, USA, European and Chinese guidelines summaries. https://www.aspirin-foundation.com/scientific-information/guidelines/

 

 

Back to top

SHARE THIS ARTICLE

Facebook
Twitter
LinkedIn
2020 10 19 11 04 56 Pdf Architect 7 → Aspirin Summaries 11 2020.pdf
Download the full summary as a PDF document.
Download PDF

Connect with us

Sign up to be part of the aspirin community and be the first to receive latest information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Have something to say about aspirin?

Contact Us Here
Footer Logo
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
TwitterLinkedin

Copyright © 2020 Aspirin Foundation

Website by mtc.

Have something to say about aspirin?

Please fill in the form below and we will contact you with further information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Djp

Daniel José Piñeiro

ASSOCIATE
Name
Daniel José Piñeiro
Academic Affiliations:
Full Professor of Medicine, Universidad de Buenos Aires, Argentina Trustee, Board of Trustees, American College of Cardiology
Professional Setting:
My academic experience includes more than 40 years as a practicing medical doctor, teacher, and researcher. I have fulfilled these appointments in settings of vital social engagement and impact, most notably at the Hospital de Clínicas “José de San Martín” of the Universidad de Buenos Aires, a public hospital with high academic recognition. Additionally, I currently hold the position of Full Professor of Medicine at that same University.
Academic Activities:
  • International Meetings Participations: 180
  • Books-Editor: 1
  • Books Chapters: 39
  • Refereed Full Articles: 118 (listed in Pubmed: 29)
  • Refereed Abstracts: 221
  • Editorial Boards: 10
Profesional Associations:
  • 2005 President, Sociedad Argentina de Cardiología.
  • 2011-2013 President, Inter-American Society of Cardiology.
  • 2011-2013 Member (ex-officio), Board of Directors, World Heart Federation
  • 2017-2018 Member (at large), Board of Directors, World Heart Federation
  • 2018-2021 Trustee, Board of Trustees, American College of Cardiology
Return to Scientific Advisory Board
Chia

John Chia

Name
John Chia MBBS (Spore), MRCP (UK), FAMS (Spore)
Academic Affiliations:

Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.

Discipline:

Medical Oncology

Scientific Interests:
  • Aspirin as adjuvant therapy in established cancers
  • Adoptive T cell therapy and Dendritic cell vaccines in the treatment of solid tumors
  • Clinical Trial Design and Management
Declaration of Conflicts of Interest:

In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.

I received grant support for investigator-initiated research from:

  • National Medical Research Council Singapore
  • Bayer AG

I hold shares in:  Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics

Return to Scientific Advisory Board
Badimon

Lina Badimon

Name
Lina Badimon BSc, PharmD, PhD, FESC, FAHA
Academic Affiliations:
Director of the Cardiovascular Science Program (ICCC) at the Hospital Santa Creu and San Pau, IIB-Sant Pau; CIBER CV. Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.
Discipline:
Pharmacology, Cardiovascular Disease
Scientific Interests:
Cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease
Declaration of Conflicts of Interest:

I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.

    Return to Scientific Advisory Board
    Ge

    Junbo Ge

    Name

    Junbo Ge

    Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.

    Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.

    Return to Scientific Advisory Board
    Langley

    Ruth Langley

    Name
    Ruth Langley PhD, FRCP
    Academic Affiliations:
    Professor of Oncology and Clinical Trials, MRC Programme Leader and Chair of the Cancer Group, MRC Clinical Trials Unit at UCL, honorary consultant in medical oncology at the Brighton and Sussex University Hospital.
    Discipline:
    Medical oncologist; trialist
    Scientific Interests:
    • Aspirin
    • Gastro-oesophageal malignancy
    • Transdermal oestrogen in the treatment of prostate cancer
    • Trials methodology
    Declaration of Conflicts of Interest:
    Has received honorarium from Bayer
    Return to Scientific Advisory Board
    Chan

    Andrew T Chan

    Name
    Andrew T. Chan MD, MPH
    Academic Affiliations:
    Chief, Clinical and Translational Epidemiology Unit, Vice Chair, Division of Gastroenterology, Massachusetts General Hospital, Boston, Co-leader, Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston.
    Discipline:
    Gastroenterology
    Scientific Interests:
    • The role of aspirin in the prevention of colorectal cancer and other cancers
    • The role of the gut microbiome in colorectal cancer and other chronic gastrointestinal diseases, including inflammatory bowel disease and diverticulitis
    • The role of diet and lifestyle in colorectal cancer and other chronic gastrointestinal cancers
    Declaration of Conflicts of Interest:

    AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award

    Click here to find the press release.

    I received consultant Bayer and Pfizer, Inc.

    I received grant support for investigator-initiated research from:

    • National Institutes of Health
    • National Cancer Institute
    • Crohn’s and Colitis Foundation
    • Bayer AG
    Return to Scientific Advisory Board
    Gaziano

    Mike Gaziano

    Name
    J Michael Gaziano MD, MPH
    Academic Affiliations:

    Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
    Discipline: Cardiology and Epidemiology

    Scientific Interests:
    I am a chronic disease epidemiologist with a particular interest in the roles that individual lifestyle choices (diet, exercise, smoking), metabolic factors (obesity, high cholesterol, and hypertension), and biochemical and genetic markers play on the risk of cardiovascular disease and other chronic illnesses. Also, of interest is the impact that vascular disease has on other organ systems, including cognitive dysfunction and renal disease. I have an interest in the design of large-scale trials and observational studies nested in large health care systems using big data analytic techniques.
    Declaration of Conflicts of Interest:

    I received consultant and speaker fees Bayer.

    I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.

    Return to Scientific Advisory Board
    Pierre A Web Photo

    Pierre Amarenco

    Name

    Pierre Amarenco, MD, FAHA, FAAN

    Academic Affiliations:
    • Professor of Neurology at Paris-Diderot Sorbonne University 
    • Chairman of the Department of Neurology and Stroke Center; Bichat University Hospital
    • Co-Director INSERM Unit-698 “Clinical Research in Atherothrombosis”
    Discipline:

    Neurology and Vascular Neurology

    Scientific Interests:
    • Understanding and preventing stroke and vascular diseases
    • Clinical trials in prevention of vascular diseases
    • Carotid intima-media thickness studies
    • Lipid trials: prevention and therapeutic –protective- evaluation
    Declaration of Conflicts of Interest:

    N/A

    Return to Scientific Advisory Board
    CarloPatrono

    Carlo Patrono

    CHAIR
    Name
    Carlo Patrono MD, FESC, FRCP
    Academic Affiliations:
    Adjunct Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy) and at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia (USA).
    Discipline:
    Clinical Pharmacology
    Scientific Interests:
    • Studying platelet activation and inhibition in diabetes mellitus
    • Studying platelet activation and inhibition in myeloproliferative neoplasms
    • Investigating the mechanism of action of low-dose aspirin in preventing colorectal cancer
    Declaration of Conflicts of Interest:

    I received consultant and speakers fees from Acticor Biotech,  Amgen,  Bayer, GlaxoSmithKline,  Tremeau,  Zambon.

    I received grant support for investigator-initiated research from:

    • AIFA (Italian Drug Agency)
    • Bayer AG
    • Cancer Research UK
    • European Commission, FP6 and FP7 Programmes

      Return to Scientific Advisory Board

      Have something to say about aspirin?

      We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.